COSA 2013* Castrate-Resistant Prostate Cancer: New Wine and its Challenges (#90)
Worldwide, prostate cancer is the second most commonly diagnosed of all cancers in men. Although hormonal manipulation of the disease is the primary therapy, progress of the disease after traditional androgen deprivation therapy remains a clinical challenge, particularly in patients who develop castrate-resistant prostate cancer (CPRC). It is defined by disease progression despite androgen deprivation therapy and may present with continuous rise in serum concentrations of PSA, progression of existing disease, or appearance of new metastases. Since 2010, a number of novel agents were approved for the management of CPRC. These agents include abiraterone, enzalutamide, cabazitaxel and sipuleucel-T. These therapies, along with docetaxel (approved in 2004), have all been shown to improve overall survival time in metastatic disease. In this talk, we will focus on the role of therapy of these agents, as well as the associated toxicities with these agents. Strategies to manage these toxicities will be discussed.
